FDA withdraws COVID and shingles vaccine findings, UAE clinics face 2 counselling risks

The US Food and Drug Administration (FDA) withdrew publication of research findings on COVID-19 and shingles vaccine safety, ABC News reported on 5 May 2026, creating a communication problem for UAE clinics rather than an immediate change in local vaccination rules.

For Dubai operators, the practical question is narrower than the US political dispute. The relevant regulator remains the Dubai Health Authority (DHA). Abu Dhabi and Al Ain providers answer to the Department of Health Abu Dhabi (DOH). Clinics in Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain should monitor the Ministry of Health and Prevention (MOHAP). None of those bodies had, as of 8 September 2026, issued a public UAE policy change tied to the FDA withdrawal.

What the FDA changed

ABC News reported that the FDA withdrew studies that tracked the safety of COVID-19 and shingles vaccines. A spokesperson for the US Department of Health and Human Services told ABC News: “The studies were withdrawn because the authors drew broad conclusions that were not supported by the underlying data.”

The same ABC News report named Robert F. Kennedy Jr., US health secretary, and said the withdrawal came during a wider reshaping of US vaccine policy. It also quoted Dr. Fiona Havers, a former Centers for Disease Control and Prevention official, who described a pattern of blocking vaccine studies. For UAE providers, the operational point is that the FDA action concerns publication control in the US. It is not a UAE recall, suspension or revised contraindication.

That distinction matters at reception desks and in physician rooms. Patients may arrive with a headline about withdrawn findings and ask whether a booked vaccine is unsafe. A clinic that sells vaccination visits should be able to show its own protocol, the current UAE regulator position and the product information used for consent.

Dubai clinics should review counselling before price campaigns

Dubai Health lists both Herpes Zoster Vaccine (Shingrix) and COVID-19 vaccination among available vaccination services on a page last updated on 26 March 2026. Its service page also lists ambulatory health centres including Al Bada’a Health Center, Al Barsha Health Center and Al Khawaneej Health Center. Private clinics should not read the US story as a reason to pause vaccination activity without a DHA circular, but they should update front-desk scripts within 7 days.

The commercial exposure sits in adult vaccination packages. Posted Dubai clinic pages in 2026 show shingles vaccine pricing at AED 300 per dose at DCDC and AED 865.50 per dose at JTS Medical Centre, with the JTS page excluding consultation or encounter fees. Those are advertised prices, not a tariff. Operators should check live payer rules before offering direct billing under Sukoon, Daman or any employer plan.

• COOs should keep one dated counselling note for COVID-19 and shingles vaccination visits.
• Medical directors should confirm contraindication, adverse-event and referral language against DHA, DOH or MOHAP guidance.
• CFOs should separate vaccine cost, consultation fee and administration fee in patient estimates.
• Marketing teams should avoid claims based on unpublished or withdrawn US research.

For shingles, the UAE policy direction has been toward adult prevention. MOHAP announced the shingles vaccine under its adult vaccination programme for people aged 50 years and above, with two doses given six months apart. Dubai clinics selling Shingrix should therefore treat eligibility, dose interval and consent documentation as the core control points.

Abu Dhabi and insurer implications

In Abu Dhabi, DOH states that selected pharmacies can provide vaccination services and PCR testing. Its page says COVID-19 vaccination in pharmacies is free of charge, PCR testing costs AED 40, and the available COVID-19 vaccine in pharmacies is Sinopharm for people aged 18 years and above. Pharmacies seeking to provide these services must apply through the TAMM platform and may contact DOH Health Facilities Licensing.

Insurers will watch this story for complaints risk rather than immediate claims cost. Thiqa is named by DOH in the pharmacy context for seasonal influenza eligibility, but shingles and COVID-19 vaccine benefits vary by plan, network and pre-authorisation rule. Claims teams at clinics should verify benefit status per patient. A general statement that a vaccine is covered can become a receivables problem within one billing cycle.

The patient-facing implication is simple. The FDA publication withdrawal does not, by itself, mean a vaccine is unavailable or unsafe in the UAE. It does mean clinics should give patients a current, regulator-specific explanation and document the discussion. In Dubai, check DHA circulars and Dubai Health service updates. In Abu Dhabi and Al Ain, check DOH service pages and Shafafiya guidance. In the northern emirates, check MOHAP announcements.

Patients seeking licensed vaccination providers can use the UAE Open Healthcare Directory, which lists 12,386+ licensed providers across 8 UAE cities, sourced from official government registers.